BRKR · US market
Bruker Corp
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$9.40bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$106.90m
- Latest-quarter run-rate earnings
- -US$251.60m
- Latest fiscal-year earnings
- -US$22.50m
- Trailing revenue
- US$3.50bn
- Latest-quarter run-rate revenue
- US$3.35bn
- Latest fiscal-year revenue
- US$3.44bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- FBT · First Trust NYSE Arca Biotechnology Index Fund4.32% weight · Holdings dated 30 June 2026
- TMAPX · Touchstone Mid Cap Fund Class A2.56% weight · Holdings dated 30 June 2026
- NSMAX · Nuveen Small/Mid Cap Value Fund Class A1.79% weight · Holdings dated 30 June 2026
- FSMEX · Fidelity Select Medical Technology and Devices Portfolio1.50% weight · Holdings dated 31 May 2026
- FITE · State Street SPDR S&P Kensho Future Security ETF1.34% weight · Holdings dated 19 August 2026
- CIPSX · Champlain Small Company Fund Class Advisor1.07% weight · Holdings dated 30 June 2026
- KOMP · State Street SPDR S&P Kensho New Economies Composite ETF0.98% weight · Holdings dated 19 August 2026
- BMED · iShares Health Innovation Active ETF0.88% weight · Holdings dated 21 August 2026
- JPSV · JPMorgan Active Small Cap Value ETF0.80% weight · Holdings dated 30 June 2026
- PRWAX · T. Rowe Price All-Cap Opportunities Fund0.73% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.